Summary
According to APO Research, the global veterinary Lyme vaccines market reached USD 147.1 million in 2024 on 6.42 million doses and is projected to reach USD 210.6 million by 2031 on 8.42 million doses (2025–2031 CAGR 5.6%, volume-led with moderating ASPs). North America supplied 88.2% of 2024 revenue and remains the growth anchor to USD 188.7 million by 2031, while Europe advances to USD 20.4 million. Recombinant subunits increase their revenue mix from 54.5% to 57.8% by 2031 as practices standardize clear claims and annual revaccination; bacterins persist in price-sensitive channels. Vendor concentration remains high: Zoetis + Boehringer Ingelheim + Elanco ≈ 83.5% of revenue in 2024, followed by Merck Animal Health and Bioveta.
Veterinary Lyme disease vaccines are companion-animal biologics used to reduce the probability and magnitude of infection with Borrelia burgdorferi sensu lato after exposure to competent Ixodes ticks. Clinical use is functionally canine; feline products exist only at marginal scale. Vaccination is risk-based and paired with acaricides and environmental tick management. Lyme-borreliae are host-adapted spirochetes maintained in enzootic cycles linking small mammals and certain birds with hard ticks; larvae and nymphs acquire organisms during a blood meal, retain them transstadially, and transmit during subsequent feedings. Upon tick attachment, vector-adapted gene programs down-shift while mammalian-phase genes up-regulate to enable migration from the midgut to salivary glands. Geographies mirror vector belts: I. scapularis (Northeast/Upper Midwest US), I. pacificus (US West Coast), I. ricinus (Europe), and I. persulcatus (northern Eurasia). North American canine disease is dominated by B. burgdorferi sensu stricto; B. garinii and B. afzelii contribute in Europe and the UK.
From a market and regulatory standpoint, only North America and Europe provide contiguous Ixodes ranges, clear biologics pathways, and stable clinical demand—conditions required for licensed products and defensible sizing. Accordingly, this report quantifies these two regions and treats Asia, South America, and Africa qualitatively to avoid over-extrapolating from heterogeneous, low-signal data.
Market size and drivers. The global Veterinary Lyme Disease Vaccines market was USD147.12 million in 2024, rising from USD116.65 million in 2020 (CAGR 5.97%). It is projected to reach USD210.61 million by 2031 (2025–2031 CAGR 5.57%), driven by volume growth (global doses 6.42→8.42 million, 2020→2031; 2025–2031 CAGR 3.79%) while price growth moderates (ASP USD22.92/dose in 2024 easing to USD22.60 in 2025, then trending toward USD25.02 by 2031). Mix shift favors recombinant subunit vaccines, which accounted for USD80.24 million (54.5%) of 2024 revenue and are expected to reach USD121.71 million (57.8%) by 2031; bacterins remain relevant in price-sensitive channels.
Regional structure. North America represented USD129.68 million (88.15%) in 2024 and is forecast to USD188.72 million by 2031 (CAGR 5.83%), sustained by high I. scapularis/pacificus prevalence, established canine vaccination norms, and specialty distribution. Europe was USD16.35 million (11.11%) in 2024, projected to USD20.39 million by 2031 (CAGR 3.34%); demand is concentrated in Poland, Germany, France, Sweden, Finland, the UK, and Romania, consistent with I. ricinus/persulcatus belts.
Competitor landscape. Based on 2024 reported volumes and realized ASPs, the leading manufacturers are Zoetis (USD50.32m), Boehringer Ingelheim (USD46.02m), Elanco (USD26.44m), Merck Animal Health (USD20.95m), and Bioveta (USD3.39m). The top three account for ~83.5% of global revenue, reflecting scale advantages in R&D, licensure, and North American commercial reach.
Figures reflect bottom-up reconciliation of company-level doses and net pricing to regional totals; feline usage is retained in totals but remains de minimis. The 2025 ASP dip is attributed to contract resets and channel mix (bacterin share/chain discounting), not to structural price erosion.
Veterinary Lyme disease vaccines are companion-animal biologics designed to reduce the probability and magnitude of infection with Borreliella (Borrelia) burgdorferi sensu lato after exposure to competent Ixodes ticks. The commercial and clinical category is functionally canine; a limited feline line exists in parts of Europe, and there are no licensed equine or food-animal products. Use is risk-based rather than core and is paired with acaricides and environmental tick management. The etiologic agents are host-adapted spirochetes maintained in an enzootic cycle linking small mammals and certain birds with hard ticks. Larval and nymphal Ixodes acquire organisms during a blood meal, retain them transstadially, and transmit during subsequent feeding. Within unfed ticks, spirochetes occupy a vector-adapted state; attachment and feeding trigger a transcriptional switch toward mammalian-phase biology, down-regulating vector-phase genes and up-regulating mammalian-phase genes as organisms exit the midgut for the salivary glands. Geographically, veterinary and human hotspots mirror vector ranges: I. scapularis in the northeastern and upper midwestern United States with a coastal Pacific belt under I. pacificus; I. ricinus across temperate Europe; and I. persulcatus across northern Eurasia. North American canine disease is dominated by B. burgdorferi sensu stricto, whereas B. garinii and B. afzelii contribute materially in Europe and the UK; stable natural foci also occur across parts of northeastern Asia.
Two vaccine platforms encompass licensed products and map onto distinct biological bottlenecks. Bacterins are inactivated whole-cell preparations that present broad antigenic repertoires; in commerce they are typically bivalent by strain in North America and trivalent in Europe to align with regional sensu lato diversity. Recombinant protein subunits are defined-composition formulations built around outer-surface lipoproteins with established protective correlates. One branch uses lipidated outer surface protein A (OspA) as a single antigen; the other pairs OspA with an engineered OspC chimeric epitope protein (“chimeritope”) that concatenates linear epitopes from multiple OspC types to extend breadth. Mechanistically, anti-OspA antibodies act mainly within the feeding tick midgut, binding OspA on vector-phase organisms and impeding survival and transmission, whereas anti-OspC antibodies act in the early mammalian window at the bite site and draining tissues, promoting neutralization and opsonophagocytic clearance before hematogenous dissemination. The responses are temporally complementary and address distinct transmission bottlenecks.
Antigen-level detail underpins both design and diagnostics. OspA is a lipidated outer-membrane lipoprotein abundantly expressed by unfed tick-phase organisms; protective B-cell epitopes cluster toward the C-terminal domain, the locus of canonical neutralizing monoclonals, and OspA is down-regulated during feeding and host entry, which explains its principal value at the vector interface and its pairing with mammalian-phase antigens in some subunits. OspC is a smaller, dimeric lipoprotein whose transcription is strongly induced during tick feeding and the first days of mammalian infection; it contributes to early tissue invasion and complement interactions and is a dominant target of early humoral responses. OspC is highly polymorphic and partitioned into dozens of phylogenetic types maintained by recombination and frequency-dependent selection; antibody responses are largely type-specific and cross-protection is limited. Chimeritope designs address this constraint by assembling immunodominant linear segments—classically from the variable L5 and H5 regions—drawn from representative OspC types into a single recombinant antigen capable of broad binding across OspC diversity. In genomic context, OspA is encoded on lp54, OspC on cp26, and the vls cassette system on lp28-1 underpins antigenic variation during persistence; this plasmid architecture explains phase-specific expression and immune evasion. Serology follows from these rules: antibodies to the VlsE-derived C6 peptide track natural infection and are not induced by OspA-only vaccination, whereas bacterins and OspC-containing subunits broaden antibody profiles and require assay selection and clinical correlation to distinguish vaccine responses from infection.
Historically, the category progressed from whole-cell to defined-antigen formulations. Early licensed canine products in the 1990s were formalin-inactivated cell-lysate bacterins (e.g., LymeVax and Galaxy Lyme). The next phase introduced recombinant OspA subunits to avoid nonessential antigens and focus on vector-phase blockade. From the mid-2010s, OspA plus OspC chimeritope formulations appeared, targeting both the tick midgut and the early mammalian phase while addressing OspC's strong polymorphism. This trajectory reflects a shift from breadth via whole-cell antigen overload to breadth-with-specificity via defined antigens, with corresponding gains in compositional clarity and mechanistic alignment to transmission biology.
The global burden aligns with vector ecology and surveillance intensity. In the United States, highest veterinary and human risk occurs from the mid-Atlantic through New England and the upper Midwest, with additional foci on the Pacific coast; in Canada, risk concentrates in southern Ontario, Québec, the Maritimes, and expanding prairie and coastal belts. In Europe, risk spans the UK and Ireland, the Benelux and Alpine corridors, Germany and Poland, the Baltics and Scandinavia, and northern Mediterranean foothills where I. ricinus is established. Across northern Eurasia, I. persulcatus supports foci from northeastern Europe through western Russia into Siberia and parts of the Far East. Outside North America and Europe many jurisdictions do not license canine Lyme vaccines and rely on acaricides and exposure management.
Current products in commerce resolve to a short, well-defined list whose differences are meaningful at the level of antigen strategy, breadth, and evidentiary posture rather than dose logistics. VANGUARD® crLyme is an OspA plus OspC chimeritope subunit; the OspC component presents a panel of linear epitopes drawn from diverse OspC types, aiming to maintain binding breadth across local OspC ecologies while pairing vector-phase interception with early mammalian-phase neutralization. This defined-composition approach yields strong titers to both components, challenge-model protection across infection and histopathology endpoints, and an extended duration-of-immunity label in its home market; trade-offs include broader serologic footprints that can complicate interpretation on certain assays and a dependence on epitope selection relative to regional OspC phylogeny.
RECOMBITEK® Lyme (rLyme) is a non-adjuvanted, lipidated OspA subunit that emphasizes a tight antigen profile and a vector-interface mechanism; benefits include minimal extraneous proteins and preserved interpretability of C6-based diagnostics, while constraints center on the absence of an explicit OspC component, making timely transmission interception and booster maintenance central to performance. Nobivac® Lyme is a bivalent bacterin built around two B. burgdorferi sensu stricto strains selected to emphasize OspA and OspC expression characteristics; it delivers broad borreliacidal responses with long field experience and a 12-month duration label in its home market, balanced against the inherent complexity of whole-cell formulations and limited public standardization of OspC expression in production cultures. Duramune® Lyme and Ultra Duramune® Lyme—and their successor branding TruCan™ Lyme and TruCan™ Ultra Lyme—are bivalent bacterins positioned for breadth and for integration into combination presentations with Leptospira or broader canine cores; strengths include robust whole-cell immunogenic breadth and portfolio flexibility, while constraints mirror the bacterin class: extraneous-antigen overhead, culture-stage expression variability, and the fact that reduced fill volume by itself does not evidence superior protection. In Europe and the UK, Borrelym 3 and Merilym 3 are trivalent bacterins that include B. afzelii, B. garinii, and B. burgdorferi sensu stricto to match regional sensu lato diversity; they are well aligned to I. ricinus regions but, as whole-cell products, share the class’s compositional constraints and have limited public species-specific protection data versus each included sensu lato species. Within the same manufacturer’s portfolio, Biocan B is a canine bacterin used where national registrations permit, and Biofel B is a niche feline bacterin available in limited jurisdictions; both follow the bacterin paradigm with corresponding advantages in breadth and constraints in specificity and transparency.
Taken together, veterinary Lyme disease vaccines are best understood as a small, mechanism-anchored category defined by two platforms, two principal antigens with distinct temporal loci of action, and a finite set of market models whose antigen strategies map directly onto transmission biology. Bacterins trade compositional complexity for breadth; OspA subunits trade breadth for precision at the vector interface; OspA plus OspC chimeritopes aim to recapture breadth with defined antigens by spanning vector and early mammalian phases. Regional epidemiology and OspC phylogeny shape optimal fit, diagnostics must be interpreted with platform awareness, and program value is maximized when vaccination is integrated with acaricides and exposure management in dogs genuinely at risk.
Report Scope (at a glance)
Licensed companion-animal Lyme vaccines only: canine and feline where approved; recombinant-subunit (incl. OspA±chimeric OspC) and inactivated bacterins. Excludes stock immunotherapies, tick preventives, and non-vaccine products. Market size = ex-manufacturer net sales: volume (k doses) and revenue (USDmn), nominal USD. History 2020–2024; base 2025; forecast 2026–2031. Segmentation by Type, Company (Zoetis, Boehringer Ingelheim, Elanco, Merck Animal Health, Bioveta; “Others”), and Region/Country (US, Canada; Germany, France, UK/GB+NI, Sweden, Finland, Poland, Denmark, Romania, Rest of Europe; Rest of World where lawfully supplied). Inclusion requires lawful access and measurable volume. Estimates triangulate regulator files, company disclosures, structured interviews, and epidemiology anchors.
Veterinary Lyme Disease Vaccines Segment by Company
Zoetis
Boehringer Ingelheim
Elanco
Merck Animal Health
Bioveta
Veterinary Lyme Disease Vaccines Segment by Type
Recombinant Subunit Vaccines
Bacterin Vaccines
Veterinary Lyme Disease Vaccines Segment by Application
Canine
Feline
Veterinary Lyme Disease Vaccines Segment by Region
North America
United States
Canada
Europe
Germany
Poland
France
Sweden
Finland
United Kingdom (GB/NI)
Romania
Denmark
Rest of Europe
Key Drivers & Barriers
Category growth is demand-led by Ixodes epidemiology, seasonality, and licensure—not channel mechanics—so administered doses track where dogs meet infected ticks and how well clinics complete priming and boosters. North America’s Northeast/Upper Midwest cohorts underpin the economics (≈88.15% of 2024 revenue on ~77% of doses at structurally higher achieved prices), while Europe adds patchy, lower-priced units under bacterin-led authorizations. From 2020 to 2024, value rose from USD116.65M to USD147.12M on price realization (global ASP from USD19.93 to USD22.92) amid flat 2022–2024 volumes; the 2025–2031 outlook pivots to unit-led growth as practices raise series completion within the same Q2–Q3 seasonal gate, taking total administrations from 6.417M in 2024 to 8.417M in 2031 (≈3.79% CAGR) and value to USD210.61M, with price drifting ~1.71% as recombinant subunits expand from 2.995M doses in 2024 to ~4.527M by 2031. Execution beats discounting: maintain uninterrupted legal access, stage inventory into endemic belts ahead of season, align antigen design and evidence with local serotypes, and drive adherence through nurse-led workflows, recalls, and one-touch wellness bundling. Key sensitivities remain tick-season length/intensity, authorization scopes (age, intervals, DoI), supply reliability through the seasonal window, and local risk salience; challenges include spatial heterogeneity, substitution by modern preventives without clear additive messaging, and Europe’s regulatory fragmentation. Sponsors that pair resilient supply with precise geotargeting, stable protocols, and mix discipline capture the modeled value step-up while preserving price integrity.
Reasons to do this study
This study is undertaken to (i) quantify North America and Europe, the only regions with contiguous Ixodes belts and stable regulatory pathways; (ii) explain the 2025 ASP dip as a function of contract resets and channel mix rather than structural erosion; (iii) forecast doses, ASP, and revenue through 2031 by type (recombinant vs bacterin), application (canine, feline—de minimis), and country, anchored to licensed-product availability and practice norms; and (iv) assess competitive positioning and route-to-market implications in a high-concentration industry.
The intended readers are manufacturers (portfolio strategy, capacity and pricing posture), distributors and corporate clinic chains (inventory and contracting), and investors (exposure, sensitivity to mix/price). By stating scope limits (NA/EU quantified; other regions treated qualitatively), methods (company-level dose × realized price reconciliation), and decision questions up front, this report provides an auditable basis for planning rather than a generic market review.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Veterinary Lyme Disease Vaccines in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Veterinary Lyme Disease Vaccines manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Veterinary Lyme Disease Vaccines sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
- Market Overview
- Product Definition
- Veterinary Lyme Disease Vaccines Market by Type
- Global Veterinary Lyme Disease Vaccines Market Size by Type, 2020 VS 2024 VS 2031
- Recombinant Subunit Vaccines
- Bacterin Vaccines
- Veterinary Lyme Disease Vaccines Market by Application
- Global Veterinary Lyme Disease Vaccines Market Size by Application, 2020 VS 2024 VS 2031
- Canine
- Feline
- Assumptions and Limitations
- Study Goals and Objectives
- Veterinary Lyme Disease Vaccines Market Dynamics
- Veterinary Lyme Disease Vaccines Industry Trends
- Veterinary Lyme Disease Vaccines Industry Drivers
- Veterinary Lyme Disease Vaccines Industry Opportunities and Challenges
- Veterinary Lyme Disease Vaccines Industry Restraints
- Global Market Growth Prospects
- Global Veterinary Lyme Disease Vaccines Revenue Estimates and Forecasts (2020-2031)
- Global Veterinary Lyme Disease Vaccines Revenue by Region
- Global Veterinary Lyme Disease Vaccines Revenue by Region: 2020 VS 2024 VS 2031
- Global Veterinary Lyme Disease Vaccines Revenue by Region (2020-2025)
- Global Veterinary Lyme Disease Vaccines Revenue by Region (2026-2031)
- Global Veterinary Lyme Disease Vaccines Revenue Market Share by Region (2020-2031)
- Global Veterinary Lyme Disease Vaccines Sales Estimates and Forecasts 2020-2031
- Global Veterinary Lyme Disease Vaccines Sales by Region
- Global Veterinary Lyme Disease Vaccines Sales by Region: 2020 VS 2024 VS 2031
- Global Veterinary Lyme Disease Vaccines Sales by Region (2020-2025)
- Global Veterinary Lyme Disease Vaccines Sales by Region (2026-2031)
- Global Veterinary Lyme Disease Vaccines Sales Market Share by Region (2020-2031)
- US & Canada & Mexico
- Europe
- China
- Asia (Excluding China)
- South America, Middle East and Africa
- Market Competitive Landscape by Manufacturers
- Global Veterinary Lyme Disease Vaccines Revenue by Manufacturers
- Global Veterinary Lyme Disease Vaccines Revenue by Manufacturers (2020-2025)
- Global Veterinary Lyme Disease Vaccines Revenue Market Share by Manufacturers (2020-2025)
- Global Veterinary Lyme Disease Vaccines Manufacturers Revenue Share Top 10 and Top 5 in 2024
- Global Veterinary Lyme Disease Vaccines Sales by Manufacturers
- Global Veterinary Lyme Disease Vaccines Sales by Manufacturers (2020-2025)
- Global Veterinary Lyme Disease Vaccines Sales Market Share by Manufacturers (2020-2025)
- Global Veterinary Lyme Disease Vaccines Manufacturers Sales Share Top 10 and Top 5 in 2024
- Global Veterinary Lyme Disease Vaccines Sales Price by Manufacturers (2020-2025)
- Global Veterinary Lyme Disease Vaccines Key Manufacturers Ranking, 2023 VS 2024 VS 2025
- Global Veterinary Lyme Disease Vaccines Key Manufacturers Manufacturing Sites & Headquarters
- Global Veterinary Lyme Disease Vaccines Manufacturers, Product Type & Application
- Global Veterinary Lyme Disease Vaccines Manufacturers' Establishment Date
- Market Competitive Analysis
- Global Veterinary Lyme Disease Vaccines Market CR5 and HHI
- 2024 Veterinary Lyme Disease Vaccines Tier 1, Tier 2, and Tier 3
- Global Veterinary Lyme Disease Vaccines Revenue by Manufacturers
- Veterinary Lyme Disease Vaccines Market by Type
- Global Veterinary Lyme Disease Vaccines Revenue by Type
- Global Veterinary Lyme Disease Vaccines Revenue by Type (2020 VS 2024 VS 2031)
- Global Veterinary Lyme Disease Vaccines Revenue by Type (2020-2031) & (US$ Million)
- Global Veterinary Lyme Disease Vaccines Revenue Market Share by Type (2020-2031)
- Global Veterinary Lyme Disease Vaccines Sales by Type
- Global Veterinary Lyme Disease Vaccines Sales by Type (2020 VS 2024 VS 2031)
- Global Veterinary Lyme Disease Vaccines Sales by Type (2020-2031) & (k doses)
- Global Veterinary Lyme Disease Vaccines Sales Market Share by Type (2020-2031)
- Global Veterinary Lyme Disease Vaccines Price by Type
- Global Veterinary Lyme Disease Vaccines Revenue by Type
- Veterinary Lyme Disease Vaccines Market by Application
- Global Veterinary Lyme Disease Vaccines Revenue by Application
- Global Veterinary Lyme Disease Vaccines Revenue by Application (2020 VS 2024 VS 2031)
- Global Veterinary Lyme Disease Vaccines Revenue by Application (2020-2031) & (US$ Million)
- Global Veterinary Lyme Disease Vaccines Revenue Market Share by Application (2020-2031)
- Global Veterinary Lyme Disease Vaccines Sales by Application
- Global Veterinary Lyme Disease Vaccines Sales by Application (2020 VS 2024 VS 2031)
- Global Veterinary Lyme Disease Vaccines Sales by Application (2020-2031) & (k doses)
- Global Veterinary Lyme Disease Vaccines Sales Market Share by Application (2020-2031)
- Global Veterinary Lyme Disease Vaccines Price by Application
- Global Veterinary Lyme Disease Vaccines Revenue by Application
- Company Profiles
- Zoetis
- Zoetis Comapny Information
- Zoetis Business Overview
- Zoetis Veterinary Lyme Disease Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
- Zoetis Veterinary Lyme Disease Vaccines Product Portfolio
- Zoetis Recent Developments
- Boehringer Ingelheim
- Boehringer Ingelheim Comapny Information
- Boehringer Ingelheim Business Overview
- Boehringer Ingelheim Veterinary Lyme Disease Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
- Boehringer Ingelheim Veterinary Lyme Disease Vaccines Product Portfolio
- Boehringer Ingelheim Recent Developments
- Elanco
- Elanco Comapny Information
- Elanco Business Overview
- Elanco Veterinary Lyme Disease Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
- Elanco Veterinary Lyme Disease Vaccines Product Portfolio
- Elanco Recent Developments
- Merck Animal Health
- Merck Animal Health Comapny Information
- Merck Animal Health Business Overview
- Merck Animal Health Veterinary Lyme Disease Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
- Merck Animal Health Veterinary Lyme Disease Vaccines Product Portfolio
- Merck Animal Health Recent Developments
- Bioveta
- Bioveta Comapny Information
- Bioveta Business Overview
- Bioveta Veterinary Lyme Disease Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
- Bioveta Veterinary Lyme Disease Vaccines Product Portfolio
- Bioveta Recent Developments
- Zoetis
- North America
- North America Veterinary Lyme Disease Vaccines Market Size by Type
- North America Veterinary Lyme Disease Vaccines Revenue by Type (2020-2031)
- North America Veterinary Lyme Disease Vaccines Sales by Type (2020-2031)
- North America Veterinary Lyme Disease Vaccines Price by Type (2020-2031)
- North America Veterinary Lyme Disease Vaccines Market Size by Application
- North America Veterinary Lyme Disease Vaccines Revenue by Application (2020-2031)
- North America Veterinary Lyme Disease Vaccines Sales by Application (2020-2031)
- North America Veterinary Lyme Disease Vaccines Price by Application (2020-2031)
- North America Veterinary Lyme Disease Vaccines Market Size by Country
- North America Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- North America Veterinary Lyme Disease Vaccines Sales by Country (2020 VS 2024 VS 2031)
- North America Veterinary Lyme Disease Vaccines Price by Country (2020-2031)
- United States
- Canada
- Mexico
- North America Veterinary Lyme Disease Vaccines Market Size by Type
- Europe
- Europe Veterinary Lyme Disease Vaccines Market Size by Type
- Europe Veterinary Lyme Disease Vaccines Revenue by Type (2020-2031)
- Europe Veterinary Lyme Disease Vaccines Sales by Type (2020-2031)
- Europe Veterinary Lyme Disease Vaccines Price by Type (2020-2031)
- Europe Veterinary Lyme Disease Vaccines Market Size by Application
- Europe Veterinary Lyme Disease Vaccines Revenue by Application (2020-2031)
- Europe Veterinary Lyme Disease Vaccines Sales by Application (2020-2031)
- Europe Veterinary Lyme Disease Vaccines Price by Application (2020-2031)
- Europe Veterinary Lyme Disease Vaccines Market Size by Country
- Europe Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- Europe Veterinary Lyme Disease Vaccines Sales by Country (2020 VS 2024 VS 2031)
- Europe Veterinary Lyme Disease Vaccines Price by Country (2020-2031)
- Germany
- France
- U.K.
- Italy
- Russia
- Spain
- Netherlands
- Europe Veterinary Lyme Disease Vaccines Market Size by Type
- China
- China Veterinary Lyme Disease Vaccines Market Size by Type
- China Veterinary Lyme Disease Vaccines Revenue by Type (2020-2031)
- China Veterinary Lyme Disease Vaccines Sales by Type (2020-2031)
- China Veterinary Lyme Disease Vaccines Price by Type (2020-2031)
- China Veterinary Lyme Disease Vaccines Market Size by Application
- China Veterinary Lyme Disease Vaccines Revenue by Application (2020-2031)
- China Veterinary Lyme Disease Vaccines Sales by Application (2020-2031)
- China Veterinary Lyme Disease Vaccines Price by Application (2020-2031)
- China Veterinary Lyme Disease Vaccines Market Size by Type
- Asia (Excluding China)
- Asia Veterinary Lyme Disease Vaccines Market Size by Type
- Asia Veterinary Lyme Disease Vaccines Revenue by Type (2020-2031)
- Asia Veterinary Lyme Disease Vaccines Sales by Type (2020-2031)
- Asia Veterinary Lyme Disease Vaccines Price by Type (2020-2031)
- Asia Veterinary Lyme Disease Vaccines Market Size by Application
- Asia Veterinary Lyme Disease Vaccines Revenue by Application (2020-2031)
- Asia Veterinary Lyme Disease Vaccines Sales by Application (2020-2031)
- Asia Veterinary Lyme Disease Vaccines Price by Application (2020-2031)
- Asia Veterinary Lyme Disease Vaccines Market Size by Country
- Asia Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- Asia Veterinary Lyme Disease Vaccines Sales by Country (2020 VS 2024 VS 2031)
- Asia Veterinary Lyme Disease Vaccines Price by Country (2020-2031)
- Japan
- South Korea
- India
- Australia
- Taiwan
- Southeast Asia
- Asia Veterinary Lyme Disease Vaccines Market Size by Type
- South America, Middle East and Africa
- SAMEA Veterinary Lyme Disease Vaccines Market Size by Type
- SAMEA Veterinary Lyme Disease Vaccines Revenue by Type (2020-2031)
- SAMEA Veterinary Lyme Disease Vaccines Sales by Type (2020-2031)
- SAMEA Veterinary Lyme Disease Vaccines Price by Type (2020-2031)
- SAMEA Veterinary Lyme Disease Vaccines Market Size by Application
- SAMEA Veterinary Lyme Disease Vaccines Revenue by Application (2020-2031)
- SAMEA Veterinary Lyme Disease Vaccines Sales by Application (2020-2031)
- SAMEA Veterinary Lyme Disease Vaccines Price by Application (2020-2031)
- SAMEA Veterinary Lyme Disease Vaccines Market Size by Country
- SAMEA Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- SAMEA Veterinary Lyme Disease Vaccines Sales by Country (2020 VS 2024 VS 2031)
- SAMEA Veterinary Lyme Disease Vaccines Price by Country (2020-2031)
- Brazil
- Argentina
- Chile
- Colombia
- Peru
- Saudi Arabia
- Israel
- UAE
- Turkey
- Iran
- Egypt
- SAMEA Veterinary Lyme Disease Vaccines Market Size by Type
- Value Chain and Sales Channels Analysis
- Veterinary Lyme Disease Vaccines Value Chain Analysis
- Veterinary Lyme Disease Vaccines Key Raw Materials
- Raw Materials Key Suppliers
- Manufacturing Cost Structure
- Veterinary Lyme Disease Vaccines Production Mode & Process
- Veterinary Lyme Disease Vaccines Sales Channels Analysis
- Direct Comparison with Distribution Share
- Veterinary Lyme Disease Vaccines Distributors
- Veterinary Lyme Disease Vaccines Customers
- Veterinary Lyme Disease Vaccines Value Chain Analysis
- Concluding Insights
- Appendix
- Reasons for Doing This Study
- Research Methodology
- Research Process
- Authors List of This Report
- Data Source
- Secondary Sources
- Primary Sources
- Disclaimer
List of Tables
Table 1 | :Global Veterinary Lyme Disease Vaccines Market Size Growth Rate by Type (US$ Million), 2020 VS 2024 VS 2031 |
Table 2 | :Recombinant Subunit Vaccines Major Manufacturers |
Table 3 | :Bacterin Vaccines Major Manufacturers |
Table 4 | :Global Veterinary Lyme Disease Vaccines Market Size Growth Rate by Application (US$ Million), 2020 VS 2024 VS 2031 |
Table 5 | :Canine Major Manufacturers |
Table 6 | :Feline Major Manufacturers |
Table 7 | :Veterinary Lyme Disease Vaccines Industry Trends |
Table 8 | :Veterinary Lyme Disease Vaccines Industry Drivers |
Table 9 | :Veterinary Lyme Disease Vaccines Industry Opportunities and Challenges |
Table 10 | :Veterinary Lyme Disease Vaccines Industry Restraints |
Table 11 | :Global Veterinary Lyme Disease Vaccines Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million) |
Table 12 | :Global Veterinary Lyme Disease Vaccines Revenue by Region (2020-2025) & (US$ Million) |
Table 13 | :Global Veterinary Lyme Disease Vaccines Revenue by Region (2026-2031) & (US$ Million) |
Table 14 | :Global Veterinary Lyme Disease Vaccines Revenue Market Share by Region (2020-2025) |
Table 15 | :Global Veterinary Lyme Disease Vaccines Revenue Market Share by Region (2026-2031) |
Table 16 | :Global Veterinary Lyme Disease Vaccines Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (k doses) |
Table 17 | :Global Veterinary Lyme Disease Vaccines Sales by Region (2020-2025) & (k doses) |
Table 18 | :Global Veterinary Lyme Disease Vaccines Sales by Region (2026-2031) & (k doses) |
Table 19 | :Global Veterinary Lyme Disease Vaccines Sales Market Share by Region (2020-2025) |
Table 20 | :Global Veterinary Lyme Disease Vaccines Sales Market Share by Region (2026-2031) |
Table 21 | :Global Veterinary Lyme Disease Vaccines Revenue by Manufacturers (US$ Million) & (2020-2025) |
Table 22 | :Global Veterinary Lyme Disease Vaccines Revenue Market Share by Manufacturers (2020-2025) |
Table 23 | :Global Veterinary Lyme Disease Vaccines Sales by Manufacturers (US$ Million) & (2020-2025) |
Table 24 | :Global Veterinary Lyme Disease Vaccines Sales Market Share by Manufacturers (2020-2025) |
Table 25 | :Global Veterinary Lyme Disease Vaccines Sales Price (USD/dose) of Manufacturers (2020-2025) |
Table 26 | :Global Veterinary Lyme Disease Vaccines Key Manufacturers Ranking, 2023 VS 2024 VS 2025 |
Table 27 | :Global Veterinary Lyme Disease Vaccines Key Manufacturers Manufacturing Sites & Headquarters |
Table 28 | :Global Veterinary Lyme Disease Vaccines Manufacturers, Product Type & Application |
Table 29 | :Global Veterinary Lyme Disease Vaccines Manufacturers' Establishment Date |
Table 30 | :Global Manufacturers Market Concentration Ratio (CR5 and HHI) |
Table 31 | :Global Veterinary Lyme Disease Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024) |
Table 32 | :Global Veterinary Lyme Disease Vaccines Revenue by Type 2020 VS 2024 VS 2031 (US$ Million) |
Table 33 | :Global Veterinary Lyme Disease Vaccines Revenue by Type (2020-2025) & (US$ Million) |
Table 34 | :Global Veterinary Lyme Disease Vaccines Revenue by Type (2026-2031) & (US$ Million) |
Table 35 | :Global Veterinary Lyme Disease Vaccines Revenue Market Share by Type (2020-2025) |
Table 36 | :Global Veterinary Lyme Disease Vaccines Revenue Market Share by Type (2026-2031) |
Table 37 | :Global Veterinary Lyme Disease Vaccines Sales by Type 2020 VS 2024 VS 2031 (k doses) |
Table 38 | :Global Veterinary Lyme Disease Vaccines Sales by Type (2020-2025) & (k doses) |
Table 39 | :Global Veterinary Lyme Disease Vaccines Sales by Type (2026-2031) & (k doses) |
Table 40 | :Global Veterinary Lyme Disease Vaccines Sales Market Share by Type (2020-2025) |
Table 41 | :Global Veterinary Lyme Disease Vaccines Sales Market Share by Type (2026-2031) |
Table 42 | :Global Veterinary Lyme Disease Vaccines Price by Type (2020-2025) & (USD/dose) |
Table 43 | :Global Veterinary Lyme Disease Vaccines Price by Type (2026-2031) & (USD/dose) |
Table 44 | :Global Veterinary Lyme Disease Vaccines Revenue by Application 2020 VS 2024 VS 2031 (US$ Million) |
Table 45 | :Global Veterinary Lyme Disease Vaccines Revenue by Application (2020-2025) & (US$ Million) |
Table 46 | :Global Veterinary Lyme Disease Vaccines Revenue by Application (2026-2031) & (US$ Million) |
Table 47 | :Global Veterinary Lyme Disease Vaccines Revenue Market Share by Application (2020-2025) |
Table 48 | :Global Veterinary Lyme Disease Vaccines Revenue Market Share by Application (2026-2031) |
Table 49 | :Global Veterinary Lyme Disease Vaccines Sales by Application 2020 VS 2024 VS 2031 (k doses) |
Table 50 | :Global Veterinary Lyme Disease Vaccines Sales by Application (2020-2025) & (k doses) |
Table 51 | :Global Veterinary Lyme Disease Vaccines Sales by Application (2026-2031) & (k doses) |
Table 52 | :Global Veterinary Lyme Disease Vaccines Sales Market Share by Application (2020-2025) |
Table 53 | :Global Veterinary Lyme Disease Vaccines Sales Market Share by Application (2026-2031) |
Table 54 | :Global Veterinary Lyme Disease Vaccines Price by Application (2020-2025) & (USD/dose) |
Table 55 | :Global Veterinary Lyme Disease Vaccines Price by Application (2026-2031) & (USD/dose) |
Table 56 | :Zoetis Company Information |
Table 57 | :Zoetis Business Overview |
Table 58 | :Zoetis Veterinary Lyme Disease Vaccines Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2020-2025) |
Table 59 | :Zoetis Veterinary Lyme Disease Vaccines Product Portfolio |
Table 60 | :Zoetis Recent Development |
Table 61 | :Boehringer Ingelheim Company Information |
Table 62 | :Boehringer Ingelheim Business Overview |
Table 63 | :Boehringer Ingelheim Veterinary Lyme Disease Vaccines Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2020-2025) |
Table 64 | :Boehringer Ingelheim Veterinary Lyme Disease Vaccines Product Portfolio |
Table 65 | :Boehringer Ingelheim Recent Development |
Table 66 | :Elanco Company Information |
Table 67 | :Elanco Business Overview |
Table 68 | :Elanco Veterinary Lyme Disease Vaccines Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2020-2025) |
Table 69 | :Elanco Veterinary Lyme Disease Vaccines Product Portfolio |
Table 70 | :Elanco Recent Development |
Table 71 | :Merck Animal Health Company Information |
Table 72 | :Merck Animal Health Business Overview |
Table 73 | :Merck Animal Health Veterinary Lyme Disease Vaccines Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2020-2025) |
Table 74 | :Merck Animal Health Veterinary Lyme Disease Vaccines Product Portfolio |
Table 75 | :Merck Animal Health Recent Development |
Table 76 | :Bioveta Company Information |
Table 77 | :Bioveta Business Overview |
Table 78 | :Bioveta Veterinary Lyme Disease Vaccines Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2020-2025) |
Table 79 | :Bioveta Veterinary Lyme Disease Vaccines Product Portfolio |
Table 80 | :Bioveta Recent Development |
Table 81 | :North America Veterinary Lyme Disease Vaccines Revenue by Type (2020-2025) & (US$ Million) |
Table 82 | :North America Veterinary Lyme Disease Vaccines Revenue by Type (2026-2031) & (US$ Million) |
Table 83 | :North America Veterinary Lyme Disease Vaccines Sales by Type (2020-2025) & (k doses) |
Table 84 | :North America Veterinary Lyme Disease Vaccines Sales by Type (2026-2031) & (k doses) |
Table 85 | :North America Veterinary Lyme Disease Vaccines Sales Price by Type (2020-2025) & (USD/dose) |
Table 86 | :North America Veterinary Lyme Disease Vaccines Sales Price by Type (2026-2031) & (USD/dose) |
Table 87 | :North America Veterinary Lyme Disease Vaccines Revenue by Application (2020-2025) & (US$ Million) |
Table 88 | :North America Veterinary Lyme Disease Vaccines Revenue by Application (2026-2031) & (US$ Million) |
Table 89 | :North America Veterinary Lyme Disease Vaccines Sales by Application (2020-2025) & (k doses) |
Table 90 | :North America Veterinary Lyme Disease Vaccines Sales by Application (2026-2031) & (k doses) |
Table 91 | :North America Veterinary Lyme Disease Vaccines Sales Price by Application (2020-2025) & (USD/dose) |
Table 92 | :North America Veterinary Lyme Disease Vaccines Sales Price by Application (2026-2031) & (USD/dose) |
Table 93 | :North America Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2020 VS 2024 VS 2031) & (US$ Million) |
Table 94 | :North America Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2020-2025) & (US$ Million) |
Table 95 | :North America Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2026-2031) & (US$ Million) |
Table 96 | :North America Veterinary Lyme Disease Vaccines Sales by Country (2020 VS 2024 VS 2031) & (k doses) |
Table 97 | :North America Veterinary Lyme Disease Vaccines Sales by Country (2020-2025) & (k doses) |
Table 98 | :North America Veterinary Lyme Disease Vaccines Sales by Country (2026-2031) & (k doses) |
Table 99 | :North America Veterinary Lyme Disease Vaccines Sales Price by Country (2020-2025) & (USD/dose) |
Table 100 | :North America Veterinary Lyme Disease Vaccines Sales Price by Country (2026-2031) & (USD/dose) |
Table 101 | :United States Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 102 | :Canada Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 103 | :Mexico Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 104 | :Europe Veterinary Lyme Disease Vaccines Revenue by Type (2020-2025) & (US$ Million) |
Table 105 | :Europe Veterinary Lyme Disease Vaccines Revenue by Type (2026-2031) & (US$ Million) |
Table 106 | :Europe Veterinary Lyme Disease Vaccines Sales by Type (2020-2025) & (k doses) |
Table 107 | :Europe Veterinary Lyme Disease Vaccines Sales by Type (2026-2031) & (k doses) |
Table 108 | :Europe Veterinary Lyme Disease Vaccines Sales Price by Type (2020-2025) & (USD/dose) |
Table 109 | :Europe Veterinary Lyme Disease Vaccines Sales Price by Type (2026-2031) & (USD/dose) |
Table 110 | :Europe Veterinary Lyme Disease Vaccines Revenue by Application (2020-2025) & (US$ Million) |
Table 111 | :Europe Veterinary Lyme Disease Vaccines Revenue by Application (2026-2031) & (US$ Million) |
Table 112 | :Europe Veterinary Lyme Disease Vaccines Sales by Application (2020-2025) & (k doses) |
Table 113 | :Europe Veterinary Lyme Disease Vaccines Sales by Application (2026-2031) & (k doses) |
Table 114 | :Europe Veterinary Lyme Disease Vaccines Sales Price by Application (2020-2025) & (USD/dose) |
Table 115 | :Europe Veterinary Lyme Disease Vaccines Sales Price by Application (2026-2031) & (USD/dose) |
Table 116 | :Europe Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2020 VS 2024 VS 2031) & (US$ Million) |
Table 117 | :Europe Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2020-2025) & (US$ Million) |
Table 118 | :Europe Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2026-2031) & (US$ Million) |
Table 119 | :Europe Veterinary Lyme Disease Vaccines Sales by Country (2020 VS 2024 VS 2031) & (k doses) |
Table 120 | :Europe Veterinary Lyme Disease Vaccines Sales by Country (2020-2025) & (k doses) |
Table 121 | :Europe Veterinary Lyme Disease Vaccines Sales by Country (2026-2031) & (k doses) |
Table 122 | :Europe Veterinary Lyme Disease Vaccines Sales Price by Country (2020-2025) & (USD/dose) |
Table 123 | :Europe Veterinary Lyme Disease Vaccines Sales Price by Country (2026-2031) & (USD/dose) |
Table 124 | :Germany Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 125 | :France Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 126 | :U.K. Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 127 | :Italy Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 128 | :Russia Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 129 | :Spain Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 130 | :Netherlands Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 131 | :Switzerland Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 132 | :Sweden Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 133 | :Poland Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 134 | :China Veterinary Lyme Disease Vaccines Revenue by Type (2020-2025) & (US$ Million) |
Table 135 | :China Veterinary Lyme Disease Vaccines Revenue by Type (2026-2031) & (US$ Million) |
Table 136 | :China Veterinary Lyme Disease Vaccines Sales by Type (2020-2025) & (k doses) |
Table 137 | :China Veterinary Lyme Disease Vaccines Sales by Type (2026-2031) & (k doses) |
Table 138 | :China Veterinary Lyme Disease Vaccines Sales Price by Type (2020-2025) & (USD/dose) |
Table 139 | :China Veterinary Lyme Disease Vaccines Sales Price by Type (2026-2031) & (USD/dose) |
Table 140 | :China Veterinary Lyme Disease Vaccines Revenue by Application (2020-2025) & (US$ Million) |
Table 141 | :China Veterinary Lyme Disease Vaccines Revenue by Application (2026-2031) & (US$ Million) |
Table 142 | :China Veterinary Lyme Disease Vaccines Sales by Application (2020-2025) & (k doses) |
Table 143 | :China Veterinary Lyme Disease Vaccines Sales by Application (2026-2031) & (k doses) |
Table 144 | :China Veterinary Lyme Disease Vaccines Sales Price by Application (2020-2025) & (USD/dose) |
Table 145 | :China Veterinary Lyme Disease Vaccines Sales Price by Application (2026-2031) & (USD/dose) |
Table 146 | :Asia Veterinary Lyme Disease Vaccines Revenue by Type (2020-2025) & (US$ Million) |
Table 147 | :Asia Veterinary Lyme Disease Vaccines Revenue by Type (2026-2031) & (US$ Million) |
Table 148 | :Asia Veterinary Lyme Disease Vaccines Sales by Type (2020-2025) & (k doses) |
Table 149 | :Asia Veterinary Lyme Disease Vaccines Sales by Type (2026-2031) & (k doses) |
Table 150 | :Asia Veterinary Lyme Disease Vaccines Sales Price by Type (2020-2025) & (USD/dose) |
Table 151 | :Asia Veterinary Lyme Disease Vaccines Sales Price by Type (2026-2031) & (USD/dose) |
Table 152 | :Asia Veterinary Lyme Disease Vaccines Revenue by Application (2020-2025) & (US$ Million) |
Table 153 | :Asia Veterinary Lyme Disease Vaccines Revenue by Application (2026-2031) & (US$ Million) |
Table 154 | :Asia Veterinary Lyme Disease Vaccines Sales by Application (2020-2025) & (k doses) |
Table 155 | :Asia Veterinary Lyme Disease Vaccines Sales by Application (2026-2031) & (k doses) |
Table 156 | :Asia Veterinary Lyme Disease Vaccines Sales Price by Application (2020-2025) & (USD/dose) |
Table 157 | :Asia Veterinary Lyme Disease Vaccines Sales Price by Application (2026-2031) & (USD/dose) |
Table 158 | :Asia Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2020 VS 2024 VS 2031) & (US$ Million) |
Table 159 | :Asia Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2020-2025) & (US$ Million) |
Table 160 | :Asia Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2026-2031) & (US$ Million) |
Table 161 | :Asia Veterinary Lyme Disease Vaccines Sales by Country (2020 VS 2024 VS 2031) & (k doses) |
Table 162 | :Asia Veterinary Lyme Disease Vaccines Sales by Country (2020-2025) & (k doses) |
Table 163 | :Asia Veterinary Lyme Disease Vaccines Sales by Country (2026-2031) & (k doses) |
Table 164 | :Asia Veterinary Lyme Disease Vaccines Sales Price by Country (2020-2025) & (USD/dose) |
Table 165 | :Asia Veterinary Lyme Disease Vaccines Sales Price by Country (2026-2031) & (USD/dose) |
Table 166 | :Japan Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 167 | :South Korea Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 168 | :India Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 169 | :Australia Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 170 | :Taiwan Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 171 | :Southeast Asia Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 172 | :SAMEA Veterinary Lyme Disease Vaccines Revenue by Type (2020-2025) & (US$ Million) |
Table 173 | :SAMEA Veterinary Lyme Disease Vaccines Revenue by Type (2026-2031) & (US$ Million) |
Table 174 | :SAMEA Veterinary Lyme Disease Vaccines Sales by Type (2020-2025) & (k doses) |
Table 175 | :SAMEA Veterinary Lyme Disease Vaccines Sales by Type (2026-2031) & (k doses) |
Table 176 | :SAMEA Veterinary Lyme Disease Vaccines Sales Price by Type (2020-2025) & (USD/dose) |
Table 177 | :SAMEA Veterinary Lyme Disease Vaccines Sales Price by Type (2026-2031) & (USD/dose) |
Table 178 | :SAMEA Veterinary Lyme Disease Vaccines Revenue by Application (2020-2025) & (US$ Million) |
Table 179 | :SAMEA Veterinary Lyme Disease Vaccines Revenue by Application (2026-2031) & (US$ Million) |
Table 180 | :SAMEA Veterinary Lyme Disease Vaccines Sales by Application (2020-2025) & (k doses) |
Table 181 | :SAMEA Veterinary Lyme Disease Vaccines Sales by Application (2026-2031) & (k doses) |
Table 182 | :SAMEA Veterinary Lyme Disease Vaccines Sales Price by Application (2020-2025) & (USD/dose) |
Table 183 | :SAMEA Veterinary Lyme Disease Vaccines Sales Price by Application (2026-2031) & (USD/dose) |
Table 184 | :SAMEA Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2020 VS 2024 VS 2031) & (US$ Million) |
Table 185 | :SAMEA Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2020-2025) & (US$ Million) |
Table 186 | :SAMEA Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2026-2031) & (US$ Million) |
Table 187 | :SAMEA Veterinary Lyme Disease Vaccines Sales by Country (2020 VS 2024 VS 2031) & (k doses) |
Table 188 | :SAMEA Veterinary Lyme Disease Vaccines Sales by Country (2020-2025) & (k doses) |
Table 189 | :SAMEA Veterinary Lyme Disease Vaccines Sales by Country (2026-2031) & (k doses) |
Table 190 | :SAMEA Veterinary Lyme Disease Vaccines Sales Price by Country (2020-2025) & (USD/dose) |
Table 191 | :SAMEA Veterinary Lyme Disease Vaccines Sales Price by Country (2026-2031) & (USD/dose) |
Table 192 | :Brazil Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 193 | :Argentina Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 194 | :Chile Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 195 | :Colombia Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 196 | :Peru Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 197 | :Saudi Arabia Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 198 | :Israel Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 199 | :UAE Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 200 | :Turkey Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 201 | :Iran Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 202 | :Egypt Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Table 203 | :Key Raw Materials |
Table 204 | :Raw Materials Key Suppliers |
Table 205 | :Veterinary Lyme Disease Vaccines Distributors List |
Table 206 | :Veterinary Lyme Disease Vaccines Customers List |
Table 207 | :Research Programs/Design for This Report |
Table 208 | :Authors List of This Report |
Table 209 | :Secondary Sources |
Table 210 | :Primary Sources |
List of Figures
Figure 1 | :Veterinary Lyme Disease Vaccines Image |
Figure 2 | :Global Veterinary Lyme Disease Vaccines Market Size Growth Rate by Type (US$ Million), 2020 VS 2024 VS 2031 |
Figure 3 | :Global Veterinary Lyme Disease Vaccines Market Size Share 2020 VS 2024 VS 2031 |
Figure 4 | :Recombinant Subunit Vaccines Image |
Figure 5 | :Bacterin Vaccines Image |
Figure 6 | :Global Veterinary Lyme Disease Vaccines Market Size Growth Rate by Application (US$ Million), 2020 VS 2024 VS 2031 |
Figure 7 | :Global Veterinary Lyme Disease Vaccines Market Size Share 2020 VS 2024 VS 2031 |
Figure 8 | :Canine Image |
Figure 9 | :Feline Image |
Figure 10 | :Global Veterinary Lyme Disease Vaccines Revenue (US$ Million), 2020 VS 2024 VS 2031 |
Figure 11 | :Global Veterinary Lyme Disease Vaccines Revenue (2020-2031) & (US$ Million) |
Figure 12 | :Global Veterinary Lyme Disease Vaccines Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million) |
Figure 13 | :Global Veterinary Lyme Disease Vaccines Revenue Market Share by Region: 2024 Versus 2031 |
Figure 14 | :Global Veterinary Lyme Disease Vaccines Revenue Market Share by Region (2020-2031) |
Figure 15 | :Global Veterinary Lyme Disease Vaccines Sales (2020-2031) & (k doses) |
Figure 16 | :Global Veterinary Lyme Disease Vaccines Sales by Region: 2020 VS 2024 VS 2031 (k doses) |
Figure 17 | :Global Veterinary Lyme Disease Vaccines Sales Market Share by Region (2020-2031) |
Figure 18 | :US & Canada & Mexico Veterinary Lyme Disease Vaccines Sales YoY (2020-2031) & (k doses) |
Figure 19 | :Europe Veterinary Lyme Disease Vaccines Sales YoY (2020-2031) & (k doses) |
Figure 20 | :China Veterinary Lyme Disease Vaccines Sales YoY (2020-2031) & (k doses) |
Figure 21 | :Asia (Excluding China) Veterinary Lyme Disease Vaccines Sales YoY (2020-2031) & (k doses) |
Figure 22 | :South America, Middle East and Africa Veterinary Lyme Disease Vaccines Sales YoY (2020-2031) & (k doses) |
Figure 23 | :Global Veterinary Lyme Disease Vaccines Manufacturers Revenue Share Top 10 and Top 5 in 2024 |
Figure 24 | :Global Veterinary Lyme Disease Vaccines Manufacturers Sales Share Top 10 and Top 5 in 2024 |
Figure 25 | :Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024 |
Figure 26 | :Global Veterinary Lyme Disease Vaccines Revenue by Type (2020 VS 2024 VS 2031) & (US$ Million) |
Figure 27 | :Global Veterinary Lyme Disease Vaccines Revenue Market Share by Type 2020 VS 2024 VS 2031 |
Figure 28 | :Global Veterinary Lyme Disease Vaccines Revenue Market Share by Type (2020-2031) |
Figure 29 | :Global Veterinary Lyme Disease Vaccines Sales by Type (2020 VS 2024 VS 2031) & (k doses) |
Figure 30 | :Global Veterinary Lyme Disease Vaccines Sales Market Share by Type 2020 VS 2024 VS 2031 |
Figure 31 | :Global Veterinary Lyme Disease Vaccines Sales Market Share by Type (2020-2031) |
Figure 32 | :Global Veterinary Lyme Disease Vaccines Revenue by Application (2020 VS 2024 VS 2031) & (US$ Million) |
Figure 33 | :Global Veterinary Lyme Disease Vaccines Revenue Market Share by Application 2020 VS 2024 VS 2031 |
Figure 34 | :Global Veterinary Lyme Disease Vaccines Revenue Market Share by Application (2020-2031) |
Figure 35 | :Global Veterinary Lyme Disease Vaccines Sales by Application (2020 VS 2024 VS 2031) & (k doses) |
Figure 36 | :Global Veterinary Lyme Disease Vaccines Sales Market Share by Application 2020 VS 2024 VS 2031 |
Figure 37 | :Global Veterinary Lyme Disease Vaccines Sales Market Share by Application (2020-2031) |
Figure 38 | :North America Veterinary Lyme Disease Vaccines Revenue Share by Type (2020-2031) |
Figure 39 | :North America Veterinary Lyme Disease Vaccines Sales Share by Type (2020-2031) |
Figure 40 | :North America Veterinary Lyme Disease Vaccines Revenue Share by Application (2020-2031) |
Figure 41 | :North America Veterinary Lyme Disease Vaccines Sales Share by Application (2020-2031) |
Figure 42 | :North America Veterinary Lyme Disease Vaccines Revenue Share by Country (2020-2031) |
Figure 43 | :North America Veterinary Lyme Disease Vaccines Sales Share by Country (2020-2031) |
Figure 44 | :Europe Veterinary Lyme Disease Vaccines Revenue Share by Type (2020-2031) |
Figure 45 | :Europe Veterinary Lyme Disease Vaccines Sales Share by Type (2020-2031) |
Figure 46 | :Europe Veterinary Lyme Disease Vaccines Revenue Share by Application (2020-2031) |
Figure 47 | :Europe Veterinary Lyme Disease Vaccines Sales Share by Application (2020-2031) |
Figure 48 | :Europe Veterinary Lyme Disease Vaccines Revenue Share by Country (2020-2031) |
Figure 49 | :Europe Veterinary Lyme Disease Vaccines Sales Share by Country (2020-2031) |
Figure 50 | :China Veterinary Lyme Disease Vaccines Revenue Share by Type (2020-2031) |
Figure 51 | :China Veterinary Lyme Disease Vaccines Sales Share by Type (2020-2031) |
Figure 52 | :China Veterinary Lyme Disease Vaccines Revenue Share by Application (2020-2031) |
Figure 53 | :China Veterinary Lyme Disease Vaccines Sales Share by Application (2020-2031) |
Figure 54 | :Asia Veterinary Lyme Disease Vaccines Revenue Share by Type (2020-2031) |
Figure 55 | :Asia Veterinary Lyme Disease Vaccines Sales Share by Type (2020-2031) |
Figure 56 | :Asia Veterinary Lyme Disease Vaccines Revenue Share by Application (2020-2031) |
Figure 57 | :Asia Veterinary Lyme Disease Vaccines Sales Share by Application (2020-2031) |
Figure 58 | :Asia Veterinary Lyme Disease Vaccines Revenue Share by Country (2020-2031) |
Figure 59 | :Asia Veterinary Lyme Disease Vaccines Sales Share by Country (2020-2031) |
Figure 60 | :SAMEA Veterinary Lyme Disease Vaccines Revenue Share by Type (2020-2031) |
Figure 61 | :SAMEA Veterinary Lyme Disease Vaccines Sales Share by Type (2020-2031) |
Figure 62 | :SAMEA Veterinary Lyme Disease Vaccines Revenue Share by Application (2020-2031) |
Figure 63 | :SAMEA Veterinary Lyme Disease Vaccines Sales Share by Application (2020-2031) |
Figure 64 | :SAMEA Veterinary Lyme Disease Vaccines Revenue Share by Country (2020-2031) |
Figure 65 | :SAMEA Veterinary Lyme Disease Vaccines Sales Share by Country (2020-2031) |
Figure 66 | :Veterinary Lyme Disease Vaccines Value Chain |
Figure 67 | :Manufacturing Cost Structure |
Figure 68 | :Veterinary Lyme Disease Vaccines Production Mode & Process |
Figure 69 | :Direct Comparison with Distribution Share |
Figure 70 | :Distributors Profiles |
Figure 71 | :Years Considered |
Figure 72 | :Research Process |
Figure 73 | :Key Executives Interviewed |
Request a Sample
Sample excerpt is intended to facilitate an informed purchase decision. Its purpose is not to offer free information or act as a substitute for the comprehensive product. In order to tailor the sample to your specific requirements, we will reach out to you to gather more details about your criteria.

Pharma & Healthcare
Global Veterinary Lyme Disease Vaccines Market Analysis and Forecast 2025-2031
Pages: 198
Complete Your Request
Customer reviews
- 0 out of 5
- 0 Reviews
5
4
3
2
1
No Rating Review Exist.
Write Review
Suggested Report
View MoreNo data found.